Startseite>>Signaling Pathways>> Proteases>> Lipoxygenase>>15-Lipoxygenase Inhibitor 1

15-Lipoxygenase Inhibitor 1 (Synonyms: 15LO Inhibitor 1)

Katalog-Nr.GC41938

15-Lipoxygenase-Inhibitor 1 ist ein selektiver Inhibitor der 15-Lipoxygenase mit einem IC50-Wert von 18 μM. 15-Lipoxygenase-Inhibitor 1 hat IC50s von 19,5 μM und 19,1 ⋼M fÜr Sojabohnen-15-Lipoxygenase (SLO) bzw. menschliche 15-Lipoxygenase-1 (15-LOX-1). 15-Lipoxygenase Inhibitor 1 hat Potenzial fÜr die Erforschung von Prostatakrebs.

Products are for research use only. Not for human use. We do not sell to patients.

15-Lipoxygenase Inhibitor 1 Chemische Struktur

Cas No.: 928853-86-5

Größe Preis Lagerbestand Menge
500μg
27,00 $
Auf Lager
1mg
52,00 $
Auf Lager
5mg
214,00 $
Auf Lager
10mg
357,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lipoxygenases (LOs) are non-heme iron-containing dioxygenases that catalyze the oxidation of polyunsaturated fatty acids to generate unsaturated fatty acid hydroperoxides. The immediate products of 15-LO fatty acid oxidation act as mediators in inflammation, thrombosis, and cancer. 15-Lipoxygenases (15-LO) inhibitor 1 is a heterocyclic pyrimidobenzothiazine compound that inhibits 15-LO with an IC50 value of 18 µM. The inhibitor appears to act as an antioxidant, interfering with the redox cycle of 15-LO.

Bewertungen

Review for 15-Lipoxygenase Inhibitor 1

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 15-Lipoxygenase Inhibitor 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.